期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

厄罗替尼治疗晚期非小细胞肺癌的副反应观察与护理 被引量：4

Observation and nursing care of subsidiary reaction of erlotini in treatment of non-small-cell lung carcinoma
下载PDF
导出
摘要 肺癌是发病率和病死率均较高的呼吸系统恶性肿瘤之一，非小细胞肺癌（non-small cell lung cancer，NSCLC）占肺癌总发病率的70％-80％，而其中1／3初次确诊时已经为局部晚期Ⅲ，治疗的目的主要在于延长生存时间及改善生活质量。
作者 朱芳 王丁兰 陈凤莲
机构地区 福建省肿瘤医院
出处 《护理研究（下旬版）》 2012年第9期2569-2570,共2页 Chinese Nursing Researsh
关键词 晚期非小细胞肺癌 厄罗替尼 治疗 副反应 呼吸系统恶性肿瘤 护理 总发病率 CELL
分类号 R473.73 [医药卫生—护理学]
  • 相关文献

参考文献11

  • 1梅同华,徐小杰.TP与NP方案治疗晚期非小细胞肺癌的疗效比较[J].中国药房,2005,16(2):127-128. 被引量：15
  • 2彭培建,林忠,张红雨,肖妹,陈楠,韩军.厄罗替尼治疗晚期非小细胞肺癌患者的疗效及安全性研究[J].中国全科医学,2010,13(13):1420-1423. 被引量：23
  • 3Lenz HJ. Anti - EGFR mechanism of action: Antitumor effect and underlying cause of adverse events[J ]. Oncology, 2006, 20 ( Suppl 2):5-13.
  • 4Trotti A, Colevas AD, Setser A, et a l. CTCAE v3.0 : Development of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Onco,2003,13(3) :176 - 181.
  • 5Bezjak A, Dongsheng T, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib:Quality of life analysis of the Nationed Cancer Institute of Canada Clinical Trials Group Study BR. 21[J]. J Clin Oncol,2006,24(24) :3831 - 3837.
  • 6Wu Y,Zhang L,Siu- kiea J,et al. Safety of erlotinib in TRUST, phase IV trial in patients with advanced non - small cell lung cancer (NSCLC) :Initial results from the East/South (E/SE) Asian subgroup[J]. J Clin Oneol,2007,25(185) :18018.
  • 7Fukuoka M, Yano S, Giaecone G, et al. Multi- institutional randomized phase H trial of gefitinib for previously treated patients with advanced nonsmall- cell lung cancer(the IDEALTrial) [J]. J Clin Oneol,2003,21(12) :2237 - 2246.
  • 8Shepherd FA, Rodrigues J, Ciuleanu T,et al. Erlotinib in previous- ly treated non - small - cell lung cancer[J]. N Engl J Med, 2005, 353(2) :123 - 132.
  • 9郭慧玲,张蓉芳,杨启梅,张玲娟,杨克虎,田金徽.厄洛替尼治疗晚期非小细胞肺癌的系统评价[J].中国肺癌杂志,2009,12(12):1229-1236. 被引量：17
  • 10黄诚,吴标,庄武,徐振武,张晶,黄韵坚.厄洛替尼一线治疗晚期非小细胞肺癌临床观察[J].中国肺癌杂志,2009,12(12):1282-1286. 被引量：4

二级参考文献54

  • 1王岩,徐建明,宋三泰.表皮生长因子受体靶向药物作用机制与相关标志物的研究现状[J].中华肿瘤杂志,2005,27(9):573-576. 被引量：33
  • 2Parkin DM, Bray F, FerlayJ, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 3Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer morality in China: 1991-2005. BrJ Cancer, 2004, 90(11): 2157-2166.
  • 4Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25 (Snppl 1): 3-10.
  • 5American Cancer Society. Cancer facts and figures 2005. Available at: http://www.cancer.org/docroot/STT/stt_O.asp. Accessed October 20th 2006.
  • 6Smith J. Erlotinib: Small molecule targeted therapy in the treatment of nonsmall-cell lung cancer. Clinical Therapeutics, 2005, 27(10): 1513-1534.
  • 7Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004, 64(24): 8919-8923.
  • 8Cohen MH,'Johnson JK, Chen YF, et al FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist, 2005, 10(7): 461.
  • 9Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ, 2001, 323 (7303):42-46.
  • 10Shepherd FA, Rodrigues Pereira J, Ciuleanu T, a al. Erlotinib in previously treated non-small-celllung cancer. N EnglJ Med, 2005, 353(2): 123-132.

共引文献55

同被引文献33

  • 1杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量：116
  • 2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：626
  • 3杨林,王金万,孙燕,朱允中,刘晓晴,李维廉,邸立军,李佩文,王友良,宋恕平,姚晨,游丽芬.重组人血管内皮抑制素YH-16治疗晚期非小细胞肺癌的临床研究[J].中华肿瘤杂志,2006,28(2):138-141. 被引量：144
  • 4徐冰河,孙燕.特罗凯可提高肺癌患者生活质量[N].肺癌论坛,2007-03-12.
  • 5Galimont - Collen AFS, Vos LE, Lavrijsen APM, et al. Classi, fica- tion and management of skin, hair, nail and mucosal side- effects of epidermal growth factor receptor(EGFR) inhibitors[J]. Eur J Cancer, 2007,43 : 845.
  • 6National Cancer Institute (NCI). Common toxicity criteria(CTC) Version 2.0[R]. Accessed February,2007 : 14.
  • 7Woodworth CD, Michael E, Marker D,et al. Inhibition of the epi dermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment [J]. Mol Cancer Ther,2005,4:650 - 658.
  • 8Susarla SM, Bergman AV, Howell TH, et al. Problem based learn- ing and research at the harvard school of dental medicine:A ten - year follow - up[J]. Journal of Dental Education, 2004,68(1) : 71 - 76.
  • 9Garetto LP, Weissinger PA,Goldblatt LI. Introducing critical think- ing into dental education[J]. Alpha Omegan, 2004,97 (2) : 28 - 34.
  • 10Michaelsen LK, Bauman KA, Fink LD. Team - based learning: A transformative use of small groups in college teaching[M]. [s. 1. ]. Sterling (VA) Stylus Publishing, 2002 : 287.

引证文献4

二级引证文献16

护理研究（下旬版）
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部